Dear editor: Xanthoma disseminatum (XD) is a rare, benign, normolipidemic mucocutaneous xanthomatosis of unknown etiology 1 . Many therapeutic options such as surgical excision, laser ablation, electrodessication, systemic medications, and radiotherapy are available, but treatment is challenging 2 . We present a male XD patient who showed marked improvement with combination of lipid lowering agents.
Successful Treatment of Xanthoma Disseminatum with Combined Lipid Lowering Agents
Won-Jeong Kim, M.D. Foamy cells could be induced by increased uptake, synthesis and decreased efflux of lipid, and the cytokines from the inflamed intima could also be triggering factors 4 .
Therefore, reducing the inflammation of the lesion and inhibiting the subsequent formation of foam cells could be an important therapeutic goal in XD. For these reasons, we previously attempted to use lipid lowering agent monotherapy in a small number of XD patients, but we saw no improvement. Thus, we attempted to use a combination of three lipid lowering agents, PPARγ, statins, and fenofibrate, modifying suggestions by Eisendle et al. 5 . PPAR γ inhibits the production of macrophage-induced inflammatory cytokines as well as reducing adipogenic action of macrophage by inducing reverse cholesterol transport 6 .
Statins are known to decrease inflammation and to inhibit the production of precursors to cholesterol synthesis 4 .
Fenofibrate, the final combination agent, activates PPARα and improves high density lipoprotein functions such as reverse cholesterol transport and anti-inflammatory activity 7 . Though the use of combination therapy of lipid lowering agents is still rare in dermatologic fields except in one reported case in XD with partial remission 5 , there are several articles reporting a superior effect of combination therapy on the treatment of hyperlipidemia 7, 8 . The mechanism of combination treatment of XD is still ambiguous; we thought it may result from decreased inflammation and reduced formation of foam cells. Before visiting our clinic, our patient's lesions showed little change after treatment and new lesions appeared continually. However, after only 8 weeks of lipid lowering agents combination therapy, the lesions were flattened, decreased in the size, and no more new lesions appeared. Therefore, we thought this patient improved with combination therapy. To our knowledge, it is a unique case of a successful outcome with combination therapy of lipid lowering agents in the treatment of XD. In our opinion, this is a promising therapy for the treatment of XD recalcitrant to other treatments.
